Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial

MLA

John F. Seymour, et al. “Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial.” Blood, vol. 134, Nov. 2019, p. 356. EBSCOhost, https://doi.org/10.1182/blood-2019-123678.

APA

John F. Seymour, Jenny Wu, Michelle Boyer, Brenda Chyla, Anne-Marie van der Kevie-Kersemaekers, Clemens Mellink, Eric Eldering, Anton W. Langerak, Barbara Eichhorst, Yanwen Jiang, Peter Hillmen, Carolyn Owen, Julie Dubois, Kathryn Humphrey, Arnon P. Kater, Christopher R. Bolen, Zoe June Assaf, Thomas J. Kipps, Jue Wang, … Marcus Lefebure. (2019). Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial. Blood, 134, 356. https://doi.org/10.1182/blood-2019-123678

Chicago

John F. Seymour, Jenny Wu, Michelle Boyer, Brenda Chyla, Anne-Marie van der Kevie-Kersemaekers, Clemens Mellink, Eric Eldering, et al. 2019. “Genome and Exome-Wide Studies Reveal Potential Predictive Efficacy Markers for Venetoclax and Rituximab (VenR) in Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL): Subgroup Analyses of the Murano Trial.” Blood 134 (November): 356. doi:10.1182/blood-2019-123678.